Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 11

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 11
---
for such information. Such information and data involves risks and uncertainties and is subject to change based on various factors, including,
potentially, those discussed under the section of this prospectus entitled “Risk Factors.” Furthermore, such information
and data cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary
nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. Additionally, while our
own internal research has not been verified by any independent source, we believe such research to be reliable and are responsible for
any information disclosed in this prospectus based upon such internal research.

<div align='center'>vi

TRADEMARKS</div>

This document contains references
to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus
may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor
will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use
or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.

<div align='center'>vii

PROSPECTUS SUMMARY</div>

This prospectus summary highlights certain information about us and selected information contained elsewhere in or incorporated by reference into this prospectus. This prospectus summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of us, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement or amendment, including the factors described under the heading “Risk Factors,” beginning on page 5 of this prospectus, as well as the information incorporated herein by reference, before making an investment decision. In this prospectus, unless the context requires otherwise, all references to “we,” “our,” “us,” “CERo,” the “Registrant,” and the “Company” refer to CERo Therapeutics Holdings, Inc.

Overview

We are an innovative immunotherapy company advancing the development
of next-generation engineered T cell therapeutics for the treatment of cancer. Our proprietary approach to T cell engineering, which enables
us to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed
to engage the